Tags

Type your tag names separated by a space and hit enter

Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
Expert Rev Anti Infect Ther. 2014 Nov; 12(11):1311-24.ER

Abstract

During the mid-nineties, 95-97% of intra-abdominal infection (IAI)- associated microbes were susceptible to commonly used antibiotics. Nowadays, in Gram-negative bacilli, β-lactam resistance and the associated co-resistance to other antibiotics leading to multidrug resistance is reaching crisis proportions. This is a critical issue in the treatment of IAIs, especially for complicated IAIs and for those of nosocomial origin in severely ill patients. In this setting, this article reviews the place in the therapeutic armamentarium of ceftolozane/tazobactam, a new cephalosporin/β-lactamase inhibitor with good activity against extended spectrum β-lactamase producing Enterobacteriaceae, with stability to AmpC β-lactamases and good anti-pseudomonal activity being stable against the most common resistance mechanisms driven by mutation in Pseudomonas aeruginosa. A profound review of its in vitro activity, in vivo efficacy in animal models, pharmacodynamics, pharmacokinetics, clinical efficacy in clinical trials in complicated IAIs and safety data is performed.

Authors+Show Affiliations

Department of Anesthesiology and Surgical Critical Care, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25139127

Citation

Maseda, Emilio, et al. "Ceftolozane/tazobactam (CXA 201) for the Treatment of Intra-abdominal Infections." Expert Review of Anti-infective Therapy, vol. 12, no. 11, 2014, pp. 1311-24.
Maseda E, Aguilar L, Gimenez MJ, et al. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Rev Anti Infect Ther. 2014;12(11):1311-24.
Maseda, E., Aguilar, L., Gimenez, M. J., & Gilsanz, F. (2014). Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Review of Anti-infective Therapy, 12(11), 1311-24. https://doi.org/10.1586/14787210.2014.950230
Maseda E, et al. Ceftolozane/tazobactam (CXA 201) for the Treatment of Intra-abdominal Infections. Expert Rev Anti Infect Ther. 2014;12(11):1311-24. PubMed PMID: 25139127.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. AU - Maseda,Emilio, AU - Aguilar,Lorenzo, AU - Gimenez,Maria-Jose, AU - Gilsanz,Fernando, Y1 - 2014/08/20/ PY - 2014/8/21/entrez PY - 2014/8/21/pubmed PY - 2015/6/16/medline KW - AmpC KW - Pseudomonas aeruginosa KW - ceftolozane/tazobactam KW - complicated intra-abdominal infections KW - enterobacteriaceae KW - extended-spectrum β-lactamases SP - 1311 EP - 24 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 12 IS - 11 N2 - During the mid-nineties, 95-97% of intra-abdominal infection (IAI)- associated microbes were susceptible to commonly used antibiotics. Nowadays, in Gram-negative bacilli, β-lactam resistance and the associated co-resistance to other antibiotics leading to multidrug resistance is reaching crisis proportions. This is a critical issue in the treatment of IAIs, especially for complicated IAIs and for those of nosocomial origin in severely ill patients. In this setting, this article reviews the place in the therapeutic armamentarium of ceftolozane/tazobactam, a new cephalosporin/β-lactamase inhibitor with good activity against extended spectrum β-lactamase producing Enterobacteriaceae, with stability to AmpC β-lactamases and good anti-pseudomonal activity being stable against the most common resistance mechanisms driven by mutation in Pseudomonas aeruginosa. A profound review of its in vitro activity, in vivo efficacy in animal models, pharmacodynamics, pharmacokinetics, clinical efficacy in clinical trials in complicated IAIs and safety data is performed. SN - 1744-8336 UR - https://www.unboundmedicine.com/medline/citation/25139127/Ceftolozane/tazobactam__CXA_201__for_the_treatment_of_intra_abdominal_infections_ L2 - https://www.tandfonline.com/doi/full/10.1586/14787210.2014.950230 DB - PRIME DP - Unbound Medicine ER -